Tenon Medical, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $4.0M
- Price
- $0.2325
- % Change (Daily % change from the live per-ticker quote feed.)
- +1.09%
- Volume
- 1.5M
Quote data as of 6:15 AM ET
About
Tenon Medical, Inc., a medical device company, engages in the development of implant for the treatment of severe lower back pain in the United States. The company offers Catamaran SI-Joint Fusion System, an invasive approach to the sacroiliac joint (SI Joint) using a titanium implant for treatment of the most common types of SI Joint disorders that cause lower back pain. It also provides Catamaran Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, transfixing the SI Joint along its longitudinal axis. Tenon Medical, Inc. was incorporated in 2012 and is headquartered in Los Gatos, California.
Quick stats
Shares outstanding17.4M
Computed float14.3M
Float sourceUnknown
Cash runway (months)1.3
Dilution risk—
Has warrants—
Has convertibles—
Active shelf (Shelf registration (e.g. Form S-3) currently in effect — the company is pre-cleared to issue and sell new shares quickly. A standing dilution risk.)—
Active ATM (At-the-market offering — a program to sell newly issued shares directly into the open market at prevailing prices, diluting existing holders over time.)—
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001560293
Websitehttps://www.tenonmed.com
AI Summary
AI-generated4d agostandardbullishregulatoryTenon Medical(R) Announces FDA 510(k) Clearance for Catamaran(R) SI Joint Fusion System
Tenon Medical received FDA 510(k) clearance for updates to its Catamaran SI Joint Fusion System, transitioning certain instruments from disposable to reusable status to enhance unit economics.
The reclassification is expected to lower per-procedure costs and capital expenditures, driving improvements in gross margins and cash flow.
Since its national launch in October 2022, over 1,500 Catamaran Fixation Devices have been implanted in patients across the United States.
Red flags
- Safe Harbor boilerplate text erroneously references 'completion of the Offering' and 'use of proceeds' despite the release regarding a regulatory clearance with no offering mentioned.